Loading clinical trials...
Loading clinical trials...
Phase Ib, Multi-center Study of Combining Rituximab, Acalabrutinib, and Durvalumab (RAD) in Primary Central Nervous System Lymphoma.
Conditions
Interventions
Rituximab
Locations
1
Taiwan
Shang-Ju Wu
Taipei, Taiwan
Start Date
February 22, 2021
Primary Completion Date
December 31, 2025
Completion Date
December 31, 2025
Last Updated
May 22, 2025
NCT07074470
NCT07198087
NCT06714370
NCT04253496
NCT00710151
Lead Sponsor
National Health Research Institutes, Taiwan
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions